Design Makes a Difference: A Meta-Analysis of Antidepressant Response Rates in Placebo-Controlled Versus Comparator Trials in Late-Life Depression
The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Objective Qualitative reviews of late-life antidepressant clinical trials suggest that antidepressant response rates in comparator trials are higher than antidepressant response rates in placebo-controlled trials. No quantitative review has been conducted to test this hypothesis.Methods A meta-analysis was conducted of all published articles in peer-reviewed journals from 1985 to the present to identify randomized clinical trials contrasting antidepressant pharmacotherapy to placebo or an active comparator in late-life depressed outpatients. Sixteen studies (nine comparator trials and seven placebo-controlled trials) were identified. Antidepressant response rates in both placebo-controlled and comparator trials were extracted and submitted for analysis using multilevel meta-analysis procedures.Results The authors found significant variability in antidepressant response rates beyond chance. This variability decreased by 27% when the authors included study type in the model. As expected, antidepressant response rates in comparator trials were significantly higher (60%) than antidepressant response rates in placebo-controlled trials (46%).Conclusion Antidepressant response rates are higher in comparator trials as compared to placebo-controlled trials. These findings have important implications for combined medication and psychotherapy trials that use placebo-controlled medication conditions because the response rates from these conditions are likely to be lower than those from unblinded conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, results of another meta-analysis comparing placebo-controlled vs. comparator trials in LLD suggest that these effects may underestimate those in clinical settings, when patient expectations of improvement may be higher303.”
From Psychobiological factors of resilience and depression in late life (2019) · cites this paper as [303]
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Multilevel analysis techniques and applications
Hox, J. J., Moerbeek, M., & van de Schoot, R. (2002) · Cited by 6,810
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Gill, J. (2005) · Encyclopedia of Social Measurement · doi:10.1016/b0-12-369398-5/00166-3 · Cited by 3,114
Multilevel Analysis: Techniques and Applications
Robinson, T. J. (2003) · Journal of the American Statistical Association · doi:10.1198/jasa.2003.s281 · Cited by 1,039
Best evidence synthesis: An intelligent alternative to meta-analysis
Slavin, R. E. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00097-a · Cited by 949
Neurobiological Mechanisms of the Placebo Effect
Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S., & Zubieta, J.-K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3458-05.2005 · Cited by 777
Roberts, J. K. (2007) · The Blackwell Encyclopedia of Sociology · doi:10.1002/9781405165518.wbeosh029 · Cited by 579
Overt versus covert treatment for pain, anxiety, and Parkinson's disease
Colloca, L., Lopiano, L., Lanotte, M., & Benedetti, F. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00908-1 · Cited by 552
Haddock, C. K., Rindskopf, D. M., & Shadish, W. R. (1998) · Psychological Methods · doi:10.1037//1082-989x.3.3.339 · Cited by 338
Self-citation
Research works printed but not linked: 1
- Wilson, 2005, Antidepressants versus placebo for the depressed elderly [Systematic Review], Cochrane Database of Systematic Reviews, 4, 4
Cited by
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Armijo‐Olivo, S., Stiles, C. R., Hagen, N. A., Biondo, P. D., & Cummings, G. G. (2012) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01516.x · Cited by 1,539
Management of Depression in Older Adults: A Review
Kok, R. M., & Reynolds, C. F. (2017) · JAMA · doi:10.1001/jama.2017.5706 · Cited by 890
Wager, T. D., Atlas, L. Y., Leotti, L. A., & Rilling, J. K. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3420-10.2011 · Cited by 328
“, 2009), depression (Kirsch et al., 2008; Sneed et al., 2008; Rutherford et al., 2010), and Parkinson’s disease (de la FuenteFernandez et al.”
BackgroundScreening for Depression in Adult Patients in Primary Care Settings: A Systematic Evidence Review
O'Connor, E. A., Whitlock, E. P., Beil, T. L., & Gaynes, B. N. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-11-200912010-00007 · Cited by 282
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Self-citationWager, T. D., van Ast, V. A., Hughes, B. L., Davidson, M. L., Lindquist, M. A., & Ochsner, K. N. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.05.044 · Cited by 264
“Understanding brain–body communication is also important for improving prevention and treatment of a number of disorders, including some with an obvious neuropsychological component, such as depression (Kirsch et al., 2008; Sneed et al., 2008), anxiety (Etkin andWager, 2007), and pain (Loggia et al.”
BackgroundThe medicalisation of misery: A critical realist analysis of the concept of depression
BENTALL, D. P. (1999) · Journal of Mental Health · doi:10.1080/09638239917427 · Cited by 223
Gold, S. M., Enck, P., Hasselmann, H., Friede, T., Hegerl, U., Mohr, D. C., & Otte, C. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30153-0 · Cited by 236
Psychobiological factors of resilience and depression in late life
Laird, K. T., Krause, B., Funes, C., & Lavretsky, H. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0424-7 · Cited by 229
Sackeim, H. A., Aaronson, S. T., Carpenter, L. L., Hutton, T. M., Mina, M., Pages, K., Verdoliva, S., & West, W. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.005 · Cited by 201
Placebo effect in the treatment of depression and anxiety
Kirsch, I. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00407 · Cited by 205
Brain Mechanisms of the Placebo Effect: An Affective Appraisal Account
Ashar, Y. K., Chang, L. J., & Wager, T. D. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-021815-093015 · Cited by 191
Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials
Rutherford, B. R., Wall, M. M., Brown, P. J., Choo, T.-H., Wager, T. D., Peterson, B. S., Chung, S., Kirsch, I., & Roose, S. P. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16020225 · Cited by 183
“In adults and older adults with major depressive disorder, mean medication response rates in comparator trials are significantly greater than the mean medication response rates in placebo-controlled trials (12, 13).”
ResultSelf-citationKok, R. M., Nolen, W. A., & Heeren, T. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.036 · Cited by 167
“not affect efficacy in the elderly (Sneed et al., 2008; Wilson et al., 2001).”
BackgroundMethodDoes Study Design Influence Outcome?
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209348 · Cited by 158
“However, they did not conduct a formal literature search, provide inclusion and exclusion criteria for the studies they examined or test whether the observed difference was statistically significant.Sneed et al. [”
BackgroundSelf-citationRole of expectations in health
Colloca, L., & Miller, F. G. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328343803b · Cited by 161
Physical Activity in Depressed Elderly. A Systematic Review
Mura, G., & Carta, M. G. (2013) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901309010125 · Cited by 137
“Interestingly, a higher placebo response rate was predicted by low baseline disorder severity [109] and, in clinical practice, patients with mild to moderate depression are likely to have a better placebo response than in clinical trials [110].”
BackgroundTripping on nothing: placebo psychedelics and contextual factors
Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M., Raz, A., & Veissière, S. P. L. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05464-5 · Cited by 164
Rutherford, B., Wager, T., & Roose, S. (2010) · Current Psychiatry Reviews · doi:10.2174/157340010790596571 · Cited by 141
Self-citationFrailty and Depression in Older Adults: A High-Risk Clinical Population
Brown, P. J., Roose, S. P., Fieo, R., Liu, X., Rantanen, T., Sneed, J. R., Rutherford, B. R., Devanand, D. P., & Avlund, K. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.04.010 · Cited by 134
Self-citationMeta-analysis comparing different behavioral treatments for late-life anxiety
Thorp, S. R., Ayers, C. R., Nuevo, R., Stoddard, J. A., Sorrell, J. T., & Wetherell, J. L. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31818b3f7e · Cited by 134
Plaßmann, H., & Weber, B. (2015) · Journal of Marketing Research · doi:10.1509/jmr.13.0613 · Cited by 136
“…patient populations that exhibit disorders related to abnormal dopaminergic functioning, such as depression (Kirsch et al. 2008; Rutherford et al. 2010; Sneed et al. 2008) and Parkinson’s disease (Benedetti et al. 2004; Lidstone et al. 2010), show relatively high pain placebo response rates.”
BackgroundLessons learned from placebo groups in antidepressant trials
Mora, M. S., Nestoriuc, Y., & Rief, W. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2010.0394 · Cited by 105
The hidden effects of blinded, placebo-controlled randomized trials: An experimental investigation
Rief, W., & Glombiewski, J. A. (2012) · Pain · doi:10.1016/j.pain.2012.09.007 · Cited by 100
“While some indirect evidence for these assumptions comes from post hoc analyses of clinical trials [11,38], this has not been shown experimentally in direct comparisons.”
BackgroundAntidepressants in elderly: Metaregression of double-blind, randomized clinical trials
Calati, R., Signorelli, M. S., Balestri, M., Marsano, A., Ronchi, D. D., Aguglia, E., & Serretti, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.053 · Cited by 106
McLennan, S. N., & Mathias, J. L. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2431 · Cited by 95
“Four studies were excluded because data was presented in a format unsuitable for meta-analysis (e.g. cognition scores were dichotomised) (Stoudemire et al., 1991; Kampf-Sherf et al., 2004; Bogner et al., 2007; Sneed et al., 2008a).”
BackgroundResultImproving Primary Care for Older Adults with Cancer and Depression
Fann, J. R., Fan, M.-Y., & Unützer, J. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0999-4 · Cited by 91
How (Not What) to Prescribe: Nonpharmacologic Aspects of Psychopharmacology
Mintz, D. L., & Flynn, D. F. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.009 · Cited by 82
Nutrition Education and Dietary Behavior Change Games: A Scoping Review
Baranowski, T., Ryan, C., Hoyos-Cespedes, A., & Lu, A. S. (2018) · Games for Health Journal · doi:10.1089/g4h.2018.0070 · Cited by 92
“There has been substantial concern about the quality of research, also called risk of bias, in general 69–74 and how to incorporate issues of quality into systematic reviews.”
Thorlund, K., Druyts, E., Wu, P., Balijepalli, C., Keohane, D., & Mills, E. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13395 · Cited by 79
Gutsmiedl, K., Krause, M., Bighelli, I., Schneider‐Thoma, J., & Leucht, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02514-2 · Cited by 88
Why We should Assess Patients’ Expectations in Clinical Trials
Frisaldi, E., Shaibani, A. I., & Benedetti, F. (2017) · Pain and Therapy · doi:10.1007/s40122-017-0071-8 · Cited by 81
Al Jurdi, R. K., Marangell, L. B., Petersen, N. J., Martinez, M., Gyulai, L., & Sajatovic, M. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318187135f · Cited by 72
Biological Age, Not Chronological Age, Is Associated with Late-Life Depression
Brown, P. J., Wall, M. M., Chen, C., Levine, M. E., Yaffe, K., Roose, S. P., & Rutherford, B. R. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx162 · Cited by 66
Self-citationInflammation, Depression, and Slow Gait: A High Mortality Phenotype in Later Life
Brown, P. J., Roose, S. P., Zhang, J., Wall, M. W., Rutherford, B. R., Ayonayon, H. N., Butters, M. A., Harris, T. B., Newman, A. B., Satterfield, S., et al. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glv156 · Cited by 73
“Similarly, although antidepressant medications are effective for treating late life depression (36), there is no evidence to suggest a beneficial effect of antidepressant medications on mobility in late life.”
BackgroundSelf-citationSignal Detection and Placebo Response in Schizophrenia: Parallels with Depression
Mallinckrodt, C. H., Zhang, L., Prucka, W. R., & Millen, B. A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4282 · Cited by 64
The Role of Patient Expectancy in Placebo and Nocebo Effects in Antidepressant Trials
Rutherford, B. R., Wall, M. M., Glass, A., & Stewart, J. W. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08797 · Cited by 58
“In Study 1, subjects whose depression met remission criteria after 12 weeks of open-label treatment were randomly assigned to 1 of 4 groups: (1) placebo for 50 weeks, (2) continued fluoxetine for 14 weeks followed by placebo for 36 weeks, (3) continued fluoxetine for 38 weeks followed by placebo for 12 weeks, or (4) c…”
MethodSelf-citationChen, J. A., Papakostas, G. I., Youn, S. J., Baer, L., Clain, A. J., Fava, M., & Mischoulon, D. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06453 · Cited by 56
“comparator in geriatric outpatients with major depressive disorder (MDD) found that response and remission rates were higher in comparator trials than placebo-controlled trials (Sneed et al., 2008).”
ResultAnother face of placebo: The lessebo effect in Parkinson disease
Mestre, T., Shah, P. S., Marras, C., TOMLINSON, G. A., & Lang, A. E. (2014) · Neurology · doi:10.1212/wnl.0000000000000340 · Cited by 59
Depression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 56
Berna, C., Kirsch, I., Zion, S. R., Lee, Y. C., Jensen, K. B., Sadler, P., Kaptchuk, T. J., & Edwards, R. R. (2017) · Pain · doi:10.1097/j.pain.0000000000000870 · Cited by 52
Bingel, U., Colloca, L., & Vase, L. (2010) · Gerontology · doi:10.1159/000322090 · Cited by 58
Hegerl, U., & Mergl, R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106930 · Cited by 56
“The size of this effect is likely to be relevant as Sneed et al. (2008) reported that antidepressant response rates in trials with two active drugs (comparative trials) were on average 60%, but only 46% in placebo-controlled trials.”
BackgroundBenedetti, F., Frisaldi, E., & Shaibani, A. I. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-104536 · Cited by 62
Rutherford, B. R., Sneed, J. R., Tandler, J. M., Rindskopf, D., Peterson, B. S., & Roose, S. P. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.04.004 · Cited by 51
Self-citationFrailty and Its Correlates in Adults With Late Life Depression
Brown, P. J., Roose, S. P., O'Boyle, K., Ciarleglio, A., Maas, B., Igwe, K. C., Chung, S., Gomez, S., Naqvi, M., Brickman, A. M., et al. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.005 · Cited by 51
Self-citationMeta-analysis: Fact or fiction? How to interpret meta-analyses
Huf, W., Kalcher, K., Pail, G., Friedrich, M.-E., Filzmoser, P., & Kasper, S. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.551544 · Cited by 48
“Meta-analysis 3 Sneed et al. (2008) examined the response rates of fi rst- and second-generation anti-depressants in placebo-controlled trials and in studies using an active agent as a comparator to assess the infl uence of study design on reported medication effi cacy.”
BackgroundMethodInfluentialCuijpers, P., Karyotaki, E., Andersson, G., Li, J., Mergl, R., & Hegerl, U. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.06.005 · Cited by 44
“Similar results have been reported by another meta-analysis [64].”
ResultA randomized, prospective pilot study of patient expectancy and antidepressant outcome
Rutherford, B. R., Marcus, S. M., Wang, P., Sneed, J. R., Pelton, G., Devanand, D., Duan, N., & Roose, S. P. (2013) · Psychological Medicine · doi:10.1017/s0033291712001882 · Cited by 43
“These findings were replicated by Sneed et al. (2008) in an analysis of nine placebo-controlled and seven comparator trials for late-life depression.”
Self-citationIt's All in Your Head: Reinforcing the Placebo Response With tDCS
Schambra, H. M., Bikson, M., Wager, T. D., DosSantos, M. F. H., & DaSilva, A. F. M. (2014) · Brain stimulation · doi:10.1016/j.brs.2014.04.002 · Cited by 49
“In pharmacological depression studies, these processes create a significant placebo response, resulting in shortterm symptomatic improvements that can match those of the drug being studied (7, 8).”
BackgroundBschor, T., & Kilarski, L. L. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1155985 · Cited by 38
“In a 3-arm trial (comparison of two antidepressants and placebo), in which the probability of receiving placebo is one-third, the efficacy of antidepressants is already lowered, and it is lowest in a classic 2-arm study, in which there is a 50% chance of receiving a placebo [45,46].”
BackgroundRutherford, B. R., Cooper, T. M., Persaud, A., Brown, P. J., Sneed, J. R., & Roose, S. P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08267 · Cited by 40
Self-citationFregni, F., Brunoni, & Jr, F. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5751 · Cited by 40
There’s More to Placebo-Related Improvement Than the Placebo Effect Alone
Andrade, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12f08124 · Cited by 37
Ma, D., Zhang, Z., Zhang, X., & Li, L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.860020 · Cited by 41
Wei, W., Karim, H. T., Lin, C., Mizuno, A. N., Andreescu, C., Karp, J. F., Reynolds, C. F., & Aizenstein, H. J. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12106 · Cited by 39
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology
Möller, H., & Broich, K. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0071-8 · Cited by 32
“The increasingly large placebo effects in clinical studies of antidepressants [18, 20, 54, 55], which are also becoming even more apparent in antipsychotic studies [24], with the result that placebo-verum differences are becoming smaller and smaller (Fig.”
Bauer, K., Lau, T., Schwille‐Kiuntke, J., Schild, S., Hauner, H., Stengel, A., Zipfel, S., & Mack, I. (2020) · European Eating Disorders Review · doi:10.1002/erv.2741 · Cited by 31
“…motivations for lifestyle change, in comparison with those in RCTs where participants are already aware at study inclusion that they may only receive the less effective intervention status (Enck, Klosterhalfen, Weimer, Horing, & Zipfel, 2011; Sneed et al., 2008; Weimer, Colloca, & Enck, 2015).”
ResultOptimizing patient expectancy in the pharmacologic treatment of major depressive disorder
Zilcha-Mano, S., Brown, P. J., Roose, S. P., Cappetta, K., & Rutherford, B. R. (2019) · Psychological Medicine · doi:10.1017/s0033291718003343 · Cited by 29
“Supporting data include reports showing that antidepressant treatment effects are consistently smaller in placebocontrolled RCTs than in open studies or active comparator trials, in which patients know they are receiving an active medication for depression (Greenberg et al., 1992; Sneed et al., 2008; Rutherford et al.…”
BackgroundSelf-citationSimpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.004 · Cited by 28
Gandelman, J. A., Kang, H., Antal, A., Albert, K. M., Boyd, B. D., Conley, A. C., NEWHOUSE, P. A., & Taylor, W. D. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12137 · Cited by 28
“We similarly observed that nicotine reduces self-referential negativity bias in LLD. Reductions in negativity bias are early predictors of antidepressant response 54 and may be fundamental to the mechanism of conventional antidepressants.”
InfluentialLicht, C. M. M., Naarding, P., Penninx, B. W. J. H., van der Mast, R. C., de Geus, E. J. C., & Comijs, H. C. (2015) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000165 · Cited by 27
Clinic Visits in Late-Life Depression Trials: Effects on Signal Detection and Therapeutic Outcome
Rutherford, B. R., Tandler, J. M., Brown, P. J., Sneed, J. R., & Roose, S. P. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.09.003 · Cited by 28
“Even among published studies, less than 60% of placebocontrolled trials of antidepressant medications to treat late life depression report a significant drug-placebo difference (6).”
BackgroundSelf-citationHegerl, U., Allgaier, A., Henkel, V., & Mergl, R. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.015 · Cited by 29
Antidepressant study design affects patient expectancy: a pilot study
Rutherford, B. R., Sneed, J. R., Devanand, D. P., Eisenstadt, R., & Roose, S. P. (2009) · Psychological Medicine · doi:10.1017/s0033291709991085 · Cited by 27
“Similar results were found in a population of patients with late-life depression (Sneed et al. 2008).”
ResultSelf-citationMotter, J. N., Devanand, D. P., Doraiswamy, P. M., & Sneed, J. R. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00249 · Cited by 27
Self-citationRutherford, B. R., Slifstein, M., Chen, C., Abi‐Dargham, A., Brown, P. J., Wall, M. W., Vanegas‐Arroyave, N., Stern, Y., Bailey, V. S., Valente, E., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.007 · Cited by 25
“LLD is among the foremost reversible risk factors for cognitive decline and the development of dementia (7,8), is frequently chronic and recurrent (9), and is often difficult to treat (10).”
BackgroundSelf-citationRetractedKirsch, I., Huedo-Medina, T. B., Pigott, H. E., & Johnson, B. T. (2018) · Psychology of Consciousness: Theory, Research, and Practice · doi:10.1037/cns0000164 · Cited by 24
Dobson, E. T., & Strawn, J. R. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0192 · Cited by 23
“The factors that affect placebo response in adults with depressive disorders (Sneed et al. 2008; Papakostas and Fava 2009; Iovieno and Papakostas 2012; Rutherford et al. 2012; Rutherford and Roose 2013) and anxiety disorders (Khan et al. 2005; Stein et al. 2006; Feltner et al. 2009; Rutherford et…”
BackgroundNeural mechanisms of expectancy-based placebo effects in antidepressant clinical trials
Zilcha-Mano, S., Wang, Z., Peterson, B. S., Wall, M. M., Chen, Y., Wager, T. D., Brown, P. J., Roose, S. P., & Rutherford, B. R. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.023 · Cited by 21
Self-citationWengler, K., Ashinoff, B. K., Pueraro, E., Cassidy, C., Horga, G., & Rutherford, B. R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00860-z · Cited by 21
Self-citationRetractedPreference in Random Assignment: Implications for the Interpretation of Randomized Trials
Macias, C., Gold, P. B., Hargreaves, W. A., Aronson, E., Bickman, L., Barreira, P. J., Jones, D. R., Rodican, C. F., & Fisher, W. H. (2009) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-009-0224-0 · Cited by 26
“…reason for preferring an intervention is based on expectations of relative efficacy, since even medication trials have shown better outcomes when participants believe a drug will be efficacious (Krell et al. 2004), as well as worse outcomes when they suspect a drug is a placebo (Sneed et al. 2008).”
BackgroundChen, J. A., Vijapura, S., Papakostas, G. I., Parkin, S. R., Kim, D. J. H., Cusin, C., Baer, L., Clain, A. J., Fava, M., & Mischoulon, D. (2015) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.12.002 · Cited by 19
Study Design Affects Participant Expectations: A Survey
Rutherford, B. R., Rose, S. A., Sneed, J. R., & Roose, S. P. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819a9181 · Cited by 20
Self-citationNelson, J. C., Gandelman, J. A., & Mackin, R. S. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.08.015 · Cited by 21
Hegerl, U., Schönknecht, P., & Mergl, R. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834dc15d · Cited by 21
“The relevance of hope induction is indicated by a study on RCTs with different numbers of treatment arms [39].”
BackgroundWhat Is the Role of Medications in Late Life Depression?
Kok, R. (2013) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2013.08.006 · Cited by 19
Lyketsos, C. G., Weiller, E., Katona, C., & Gorwood, P. A. P. M. (2011) · BMC Geriatrics · doi:10.1186/1471-2318-11-2 · Cited by 18
“[23] also found higher response rates in patients in comparator trials (60% response) compared with placebo-controlled trials (46% response).”
ResultColloca, L. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.04.001 · Cited by 17
Improving study design for antidepressant effectiveness assessment
Naudet, F., Millet, B., Reymann, J. M., & Falissard, B. (2013) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1391 · Cited by 17
“The likelihood of response and remission is significantly higher in comparator versus placebo-controlled trials (Naudet et al., 2011; Rutherford et al., 2010; Rutherford et al., 2009; Sinyor et al., 2010; Sneed et al., 2008).”
ResultMendez, E. M., Mills, J. A., Suresh, V., Stimpfl, J. N., & Strawn, J. R. (2024) · CNS Spectrums · doi:10.1017/s1092852924000142 · Cited by 15
“17,35,37 This is particularly important because placebo response undermines our ability to detect efficacy signals for new medications, potentially increasing the likelihood that effective treatments are not identified nor made available to our patients.”
BackgroundGaudiano, B. A., Hughes, J. A., & Miller, I. W. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.06.003 · Cited by 16
“Intriguing evidence comes from meta-analyses showing that response rates in antidepressant trials are higher in active comparator studies (medication vs medication) compared with placebo-controlled studies (medication vs placebo) [10,11].”
BackgroundWhy does the world have such a `down' on antidepressants?
Nutt, D., & Al, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091877 · Cited by 14
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.031 · Cited by 13
“…group have reported that response to antidepressant medication is significantly greater in comparator (i.e., one medication vs. a different medication) study designs as opposed to placebo-controlled trials (i.e., one or more medications vs. placebo) (Rutherford et al., 2009; Sneed et al., 2008).”
MethodResultInfluentialSelf-citationIs placebo useful in the treatment of major depression in clinical practice?
Marchesi, C., Panfilis, C. D., Tonna, M., & Ossola, P. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s44519 · Cited by 16
“Also, in a previous report, response rates to antidepressants were lower in placebo-controlled trials (46%) than in trials comparing the effect of two antidepressants (60%).(34) These studies suggest that the patient’s expectation of receiving an antidepressant increases the placebo response, whereas the expectation t…”
Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression
Rutherford, B. R., Choi, C. J., Choi, J.-W., Mass, B., He, X., O'Boyle, K., Sneed, J. R., Brown, P. J., Brickman, A. M., Wall, M. M., et al. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.11.001 · Cited by 13
Self-citationLavie, I., Beeri, M. S., Schwartz, Y., Soleimani, L., Heymann, A. D., Azuri, J., & Ravona‐Springer, R. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad008 · Cited by 12
Kerschbaumer, A., Stimakovits, N. M., Smolen, J. S., Stefanova, T., Chwala, E., & Aletaha, D. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223349 · Cited by 12
Depression, Chemical Imbalances, and Feminism
Schultz, W., & Hunter, N. (2016) · Journal of Feminist Family Therapy · doi:10.1080/08952833.2016.1235523 · Cited by 14
“Kirsch (2010) referred to a meta-analysis by Sneed et al. (2008) which identified significantly higher response rates in comparator trials (60”
MethodAntidepressants for older people: What can we learn from the current evidence base?
Katona, C., Bindman, D., & Katona, C. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.016 · Cited by 11
Expectations mediate objective physiological placebo effects
Malani, A., & Houser, D. E. (2008) · Advances in health economics and health services research · doi:10.1016/s0731-2199(08)20013-0 · Cited by 11
Zilcha‐Mano, S., Wallace, M. L., Brown, P. J., Sneed, J. R., Roose, S. P., & Rutherford, B. R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01606-1 · Cited by 10
Self-citationMallo, C. J., & Mintz, D. L. (2013) · Psychodynamic Psychiatry · doi:10.1521/pdps.2013.41.1.13 · Cited by 15
Sugarman, M. A. (2016) · Journal of Mental Health · doi:10.3109/09638237.2016.1139071 · Cited by 11
“Inclusion of a pill placebo condition creates a bias against the active medication in these trials, as effect sizes are typically larger for comparisons between two antidepressants than between an antidepressant and a placebo (Sneed et al., 2008), likely because patients are assured that they received an active”
Backgroundvan Essen, K., Akse, M., Pelgrim, T. C., Prick, A.-E. J. C., & Aalbers, S. (2025) · The Arts in Psychotherapy · doi:10.1016/j.aip.2025.102289 · Cited by 11
Unmet needs and research challenges for late-life mood disorders
Ghio, L., Vaggi, M., Amore, M., Ferrannini, L., & Natta, W. M. (2013) · Aging Clinical and Experimental Research · doi:10.1007/s40520-013-0149-z · Cited by 9
“In addition to the aforementioned issues regarding a placebo-controlled trial [63, 64], it should be noted that TAU refers to an extremely variable range of interventions, all of which need to be clearly understood to evaluate the effectiveness of a new treatment.”
BackgroundResultAndrews, P., Vega, J. N., Szymkowicz, S. M., NEWHOUSE, P. A., Tyndale, R. F., Elson, D. M., Kang, H., Siddiqi, S., Tyner, E. B., Mather, K., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.025 · Cited by 9
Differing antidepressant maintenance methodologies
Safer, D. J. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.021 · Cited by 9
Metadata
- Authors
- Sneed, J. R., Rutherford, B. R., Rindskopf, D., Lane, D. T., Sackeim, H. A., & Roose, S. P.
- Affiliations
- New York State Psychiatric Institute (US)
- The Graduate Center, CUNY (US)
- Corresponding author
- Sneed, Joel R.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 16
- Issue
- 1
- Pages
- 65-73
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W1979782653
- Cited by
- 140
- References
- 43
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 3 · 2021: 2 · 2020: 10 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 10 · 2015: 11 · 2014: 5 · 2013: 14 · 2012: 7
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (T32MH020004, T32 MH 20004, K23 MH 70056-01A1, K23MH085236, T32MH015144)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- geriatric depression, antidepressant treatment, older adults, unblinding, trial design bias
- MeSH terms
- Age Factors, Aged, Antidepressive Agents, Depressive Disorder, Humans, Placebos, Research Design, Models, Statistical, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.